PGM3 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population derived from the Raji B-lymphocyte lineage, designed for loss-of-function studies of the phosphoglucomutase 3 (PGM3) gene. The product is generated through transient delivery of CRISPR/Cas9 components targeting PGM3, resulting in a heterogeneous pool of edited cells with disruption of the target gene across the population. This format provides a robust and cost-effective platform for assessing gene function without clonal selection, enabling researchers to quickly interrogate the hexosamine biosynthetic pathway in a B-cell lymphoma context. The polyclonal nature preserves the genetic diversity of the parental line, facilitating studies on pathway dependency and adaptive responses to gene perturbation. As with all CRISPR/Cas9-edited polyclonal populations, bulk genotyping and functional validation at the population level are recommended prior to downstream assays.
The host cell line, Raji, is an Epstein-Barr virus (EBV)-positive human B lymphocyte line originally derived from a Burkitt’s lymphoma patient. It is widely employed as a model system for B-cell malignancies, exhibiting characteristics of germinal center B cells and expressing surface markers such as CD19, CD20, and CD10. Raji cells proliferate rapidly in suspension culture and retain key features of lymphomagenesis, including aberrant activation of NF-??B and c-Myc signaling networks, making them well suited for investigating oncogenic mechanisms and therapeutic interventions. The EBV-positive status of Raji cells adds an additional layer of relevance for studying viral-driven lymphomagenesis and immune evasion strategies. This established cell line has been extensively used in drug screening, apoptosis research, and glycosylation studies, providing a consistent background for gene-editing applications.
PGM3 encodes a phosphoglucomutase that catalyzes the interconversion of N-acetylglucosamine-6-phosphate (GlcNAc-6-P) and GlcNAc-1-phosphate (GlcNAc-1-P) within the hexosamine biosynthetic pathway, a reaction essential for the production of UDP-N-acetylglucosamine (UDP-GlcNAc). UDP-GlcNAc serves as the obligate donor substrate for O-GlcNAc transferase (OGT), which catalyzes O-GlcNAcylation of serine and threonine residues on numerous nuclear and cytoplasmic proteins, including c-Myc, p53, and NF-??B, and also feeds into N-glycan biosynthesis via uridine diphosphate-N-acetylglucosamine:polypeptide N-acetylgalactosaminyltransferases and other glycosyltransferases such as MGATs and ST6GAL1. PGM3 acts downstream of glutamine fructose-6-phosphate amidotransferase 1 (GFPT1) and glucosamine-phosphate N-acetyltransferase 1 (GNPNAT1), and upstream of UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1). Its activity is regulated by upstream factors including mTORC1, SP1 transcription factor, glucose flux, and glutamine availability, integrating nutrient status with post-translational modification networks.
The disruption of PGM3 in Raji cells profoundly impacts the hexosamine biosynthetic pathway, leading to reduced UDP-GlcNAc pools and consequent impairments in both O-GlcNAcylation and N-glycosylation. In the context of B-cell lymphoma, this perturbation alters glycoprotein function on the cell surface and within intracellular compartments, disrupting signaling cascades that control proliferation, survival, and apoptosis. Given the established roles of O-GlcNAcylation in regulating oncogenic transcription factors such as c-Myc and the NF-??B complex, PGM3 knockout provides a valuable tool for dissecting glycosylation-dependent regulation of lymphoma growth. The Raji background further enables investigation of how EBV latency may modulate or compensate for hexosamine pathway blockade, offering insights into metabolic vulnerabilities and potential therapeutic targets.
This knockout cell population is ideally suited for a range of experimental applications, including functional dissection of the hexosamine biosynthetic pathway in B-cell malignancy, modeling congenital disorders of glycosylation such as PGM3-CDG, and exploring metabolic reprogramming in lymphoma cells. Researchers can employ quantitative UDP-GlcNAc analysis by LC-MS, O-GlcNAc western blotting, lectin flow cytometry for cell-surface glycan profiling, and N-glycan mass spectrometry to systematically characterize glycosylation defects. Cell-based assays such as MTT-based proliferation measurements and Annexin V apoptosis staining allow direct assessment of phenotypic consequences. Furthermore, these cells serve as a platform for validating small-molecule inhibitors targeting hexosamine pathway enzymes or for rescue experiments with wild-type PGM3. For additional information, technical support, or custom modifications, please contact Ascent Research.
